At the early draft stage of our project, the Human Practice department assisted the Wet Lab team in finding collaborative laboratories. Engaging with experts from various fields allowed us to make iterative adjustments to our project, gradually shaping it into its current form.
Since the drug we are producing is Levodopa, and there are many misconceptions about Parkinson's disease among the Taiwanese public, we believe that spreading information about Parkinson's disease is a crucial aspect of our Human Practice project design. This approach not only aims to provide assistance through our experimental results but also to support the project's direct beneficiaries from a humanitarian perspective. To achieve this, we created a podcast channel to share team stories, provide information about Parkinson's disease, and introduce synthetic biology. We also published a series of posts on Instagram related to synthetic biology and Parkinson's disease. Additionally, we organized lectures to engage high school students, making Parkinson's disease a topic that transcends age and allowing our project to reach a broader audience.
As we began to see experimental progress, we wanted to understand the market acceptance of our results. The Human Practice department started planning interviews with industry professionals and Parkinson's drug experts. Through this process, we realized that our project’s beneficiaries extend beyond just those living with Parkinson's disease; there is greater potential for our production model to be applied to different compounds, providing a new idea for the field of synthetic biology.
For more detailed information, please refer to other pages on Human Practice.